Lindbrook Capital, LLC Adaptimmune Therapeutics PLC Transaction History

Lindbrook Capital, LLC

  • $1.18 Billion
  • Q3 2024

A detailed history of Lindbrook Capital, LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Lindbrook Capital, LLC holds 4,847 shares of ADAP stock, worth $3,199. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,847
Previous 4,610 5.14%
Holding current value
$3,199
Previous $4,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024
BUY
$0.92 - $1.39 $218 - $329
237 Added 5.14%
4,847 $4,000
Q2 2024

Jul 31, 2024
SELL
$0.83 - $1.47 $1,772 - $3,138
-2,135 Reduced 31.65%
4,610 $4,000
Q1 2024

Apr 25, 2024
BUY
$0.7 - $1.75 $1,494 - $3,736
2,135 Added 46.31%
6,745 $10,000
Q2 2023

Jul 28, 2023
BUY
$0.9 - $1.51 $4,149 - $6,961
4,610 New
4,610 $4,000
Q3 2022

Nov 10, 2022
BUY
$1.06 - $2.41 $2,931 - $6,666
2,766 Added 869.81%
3,084 $3,000
Q2 2022

Aug 01, 2022
BUY
$1.33 - $2.28 $184 - $316
139 Added 77.65%
318 $1,000
Q1 2022

Apr 21, 2022
SELL
$1.73 - $4.06 $5,356 - $12,569
-3,096 Reduced 94.53%
179 $0
Q4 2021

Jan 18, 2022
SELL
$3.5 - $5.68 $18,872 - $30,626
-5,392 Reduced 62.21%
3,275 $12,000
Q3 2021

Nov 05, 2021
BUY
$3.44 - $6.37 $7,076 - $13,103
2,057 Added 31.12%
8,667 $45,000
Q2 2021

Jul 27, 2021
BUY
$3.86 - $5.78 $19,300 - $28,900
5,000 Added 310.56%
6,610 $28,000
Q3 2020

Nov 03, 2020
SELL
$7.66 - $10.78 $18,751 - $26,389
-2,448 Reduced 60.33%
1,610 $13,000
Q2 2020

Jul 27, 2020
BUY
$2.58 - $12.1 $8,049 - $37,752
3,120 Added 332.62%
4,058 $41,000
Q1 2020

Apr 22, 2020
BUY
$1.2 - $4.52 $1,125 - $4,239
938 New
938 $3,000

Others Institutions Holding ADAP

# of Institutions
82
Shares Held
150M
Call Options Held
60.8K
Put Options Held
5.8K
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $108M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email